?25.4 million in Cash and Cash equivalents as of September 30, 2016
Strasbourg, France, October 20, 2016, 7:30 am CET – Transgene (Euronext Paris: TNG), a company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases, today published its quarterly financial results as of September 30, 2016. The Company also announced today the launch of a share capital increase with shareholders’ preferential subscription rights for a total gross amount of c. ?48.1 million.
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.72 (c)||4.62%||293 431|